Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and Ponatinib in Ph+ and/or BCR-ABL+ ALL
NCT03263572Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab and ponatinib in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Complete molecular response rate at 18 weeks, Overall response rate at 12 weeks and 3 more. Started Nov 2017; status: recruiting.
02
Drugs
blinatumomabponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03263572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263572.